Patents by Inventor Torben Lessmann

Torben Lessmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIPEPTIDE-BASED PRODRUG LINKERS FOR ALIPHATIC AMINE-CONTAINING DRUGS
    Publication number: 20130053301
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
    Type: Application
    Filed: January 21, 2011
    Publication date: February 28, 2013
    Applicant: Ascendis Pharma A/S
    Inventors: Harald Rau, Torben Lessmann
  • CARRIER-LINKED CARBAMATE PRODRUG LINKERS
    Publication number: 20130035635
    Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate D-L, wherein D being a biologically active moiety containing an aromatic hydroxyl group is conjugated to one or more polymeric carriers via secondary carbamate-containing linkers L. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives. The invention also relates to pharmaceutical compositions comprising said prodrugs and their use as medicaments.
    Type: Application
    Filed: January 21, 2011
    Publication date: February 7, 2013
    Applicant: ASCENDIS PHARMA A/S
    Inventors: Harald Rau, Torben Lessmann
  • LONG ACTING INSULIN COMPOSITION
    Publication number: 20120183616
    Abstract: The present invention relates to a pharmaceutical composition comprising an insulin compound in a concentration that is sufficient to maintain a therapeutically effective level of the insulin compound in blood plasma for at least 3 days characterized by having a pharmacokinetic profile in vivo with substantially no burst of the insulin compound. The present invention further relates to the use of an insulin compound for preparing said pharmaceutical composition as well as a kit of parts comprising said pharmaceutical composition.
    Type: Application
    Filed: July 30, 2010
    Publication date: July 19, 2012
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Kennett Sprogoe, Felix Cleemann, Ulrich Hersel, Silvia Kaden-Vagt, Torben Lessmann, Harald Rau, Thomas Wegge